(Q38075482)

English

Background and rationale for revised clinical and laboratory standards institute interpretive criteria (Breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: I. Cephalosporins and Aztreonam

scientific article published on 18 January 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

1 reference

Europe PubMed Central

Background and rationale for revised clinical and laboratory standards institute interpretive criteria (Breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: I. Cephalosporins and Aztreonam (English)

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Pseudomonas aeruginosa

0 references

1 reference

based on heuristic

inferred from title

Enterobacteriaceae

1 reference

based on heuristic

inferred from title

Sujata M Bhavnani

3

object named as

Sujata M Bhavnani

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

6

object named as

Ronald N Jones

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

author name string

Michael N Dudley

1

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Paul G Ambrose

2

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

William A Craig

4

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Mary Jane Ferraro

5

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Antimicrobial Susceptibility Testing Subcommittee of the Clinical and Laboratory Standards Institute

7

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

language of work or name

0 references

publication date

18 January 2013

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Clinical Infectious Diseases

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

56

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

1301-1309

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT017

21 January 2018

Infections with extended-spectrum beta-lactamase-producing enterobacteriaceae: changing epidemiology and drug treatment choices

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT017

21 January 2018

Pharmacodynamics in the study of drug resistance and establishing in vitro susceptibility breakpoints: ready for prime time

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT017

21 January 2018

Treatment of infections with ESBL-producing organisms: pharmacokinetic and pharmacodynamic considerations.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT017

21 January 2018

Failure of current cefepime breakpoints to predict clinical outcomes of bacteremia caused by gram-negative organisms

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT017

21 January 2018

Outcomes evaluation of patients with ESBL- and non-ESBL-producing Escherichia coli and Klebsiella species as defined by CLSI reference methods: report from the SENTRY Antimicrobial Surveillance Program.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT017

21 January 2018

Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT017

21 January 2018

Cefazolin and enterobacteriaceae: rationale for revised susceptibility testing breakpoints

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT017

21 January 2018

Reevaluation of Enterobacteriaceae MIC/disk diffusion zone diameter regression scattergrams for 9 beta-lactams: adjustments of breakpoints for strains producing extended spectrum beta-lactamases

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT017

21 January 2018

Is cefepime safe for clinical use? A Bayesian viewpoint

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT017

21 January 2018

Antimicrobial Resistance: Pharmacokinetics‐Pharmacodynamics of Antimicrobial Therapy: It’s Not Just for Mice Anymore

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT017

21 January 2018

Identifiers

10.1093/CID/CIT017

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

release_72msisxigvfelae4gibg4rafwm

1 reference

https://api.fatcat.wiki/v0/release/72msisxigvfelae4gibg4rafwm

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38075482&oldid=2155753398"